Generic name: elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg, tenofovir alafenamide fumarate 10mg
Dosage form: tablet
Medically reviewed on November 29, 2017.
Testing Prior to Initiation and During Treatment with GENVOYA
Prior to initiation of GENVOYA, patients should be tested for hepatitis B virus infection [see Warnings and Precautions (5.1)].
Prior to and during treatment, as clinically appropriate, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients, and also assess serum phosphorus in patients with chronic kidney disease [see Warnings and Precautions (5.4)].
GENVOYA is a four-drug fixed dose combination product containing 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide (TAF). The recommended dosage of GENVOYA is one tablet taken orally once daily with food in adults and pediatric patients with body weight at least 25 kg and creatinine clearance greater than or equal to 30 mL per minute [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
Not Recommended in Patients with Severe Renal Impairment
GENVOYA is not recommended in patients with estimated creatinine clearance below 30 mL per minute [see Use in Specific Populations (8.6)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Genvoya (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide)
- Genvoya Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- 85 Reviews
- Drug class: antiviral combinations